AMPLY Discovery, a drug discovery startup, has raised strategic investment from Keeps Biomed, a subsidiary of South Korean specialist biotech company Keeps Biopharma. The investment is accompanied by an agreement between the companies to explore future collaboration opportunities in oncology.
The company also announced the appointment of Dr Oliver Rausch as Chief Scientific Officer. Dr Rausch joins from Storm Therapeutics and brings expertise in RNA biology and oncology drug discovery to accelerate target validation, portfolio progression and partner readiness.
AMPLY applies AI to mine multi-omic datasets and uncover disease-relevant signals, including non-coding genomic regions. It validates findings through iterative laboratory testing, enabling the rapid prioritisation of high-quality therapeutic programmes for partnering. Spun out of Queen’s University Belfast, AMPLY operates a portfolio model that generates multiple discovery programmes in therapeutic areas of high unmet need, with a focus on producing licensable assets and partnering opportunities at defined value-creation milestones.
This strategic investment is an important endorsement of AMPLY’s platform and our approach to oncology. We’re building a company designed for partnering - generating high-quality, data-driven programmes and taking them to clear inflection points. We’re delighted to welcome Keeps Biomed as a strategic investor, and to bring Oliver on board as CSO to help sharpen our oncology execution and partnering readiness.
Ben Thomas, Co-founder & CEO
We see significant opportunity in applying advanced AI-enabled discovery approaches to build a differentiated oncology pipeline. AMPLY’s platform and team align strongly with our strategic direction, and we look forward to developing collaboration opportunities in oncology.
Ha Young Kim, CEO of Keeps Biomed
AMPLY’s platform integrates cutting-edge biological insights and experimental validation - exactly what’s needed to translate computational discovery into credible therapeutic programmes. I’m excited to join the team and help drive oncology programmes towards the kind of robust datasets and development plans that partners and investors expect.
Oliver Rausch, CSO
